Patents by Inventor Ryuichi Motoda

Ryuichi Motoda has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 8883495
    Abstract: The present invention has objects to provide a novel human T-cell population having both cytotoxic and immunosuppressive activities, and to a method for preparing the same. The above objects are attained by providing a human T-cell population which is obtainable by coculturing mononuclear cells, collected from human blood, with stroma cells and which has the following features: (1) being positive for CD3, CD25, CD28 and T-cell antigen receptor ??; (2) essentially consisting of three groups of a CD4 positive and CD8 positive (CD4+CD8+) T-cell group, a CD4 positive and CD8 dimly positive (CD4+CD8dim) T-cell group, and a CD4 negative and CD8 positive (CD4?CD8+) T-cell group; (3) exerting a cytotoxic activity against the cocultured stroma cells; and (4) exerting an immunosuppressive activity against activated T cells.
    Type: Grant
    Filed: March 15, 2007
    Date of Patent: November 11, 2014
    Assignee: Hayashibara Co., Ltd.
    Inventors: Shuji Nakamura, Ryuichi Motoda, Masayoshi Kibata, Kunzo Orita, Fumiyuki Yamasaki
  • Publication number: 20090297490
    Abstract: The present invention has objects to provide a novel human T-cell population having both cytotoxic and immunosuppressive activities, and to a method for preparing the same. The above objects are attained by providing a human T-cell population which is obtainable by coculturing mononuclear cells, collected from human blood, with stroma cells and which has the following features: (1) being positive for CD3, CD25, CD28 and T-cell antigen receptor ??; (2) essentially consisting of three groups of a CD4 positive and CD8 positive (CD4+CD8?) T-cell group, a CD4 positive and CD8 dimly positive (CD4+CD8dim) T-cell group, and a CD4 negative and CD8 positive (CD4?CD8+) T-cell group; (3) exerting a cytotoxic activity against the cocultured stroma cells; and (4) exerting an immunosuppressive activity against activated T cells.
    Type: Application
    Filed: March 15, 2007
    Publication date: December 3, 2009
    Inventors: Shuji Nakamura, Ryuichi Motoda, Masayoshi Kibata, Kunzo Orita, Fumiyuki Yamasaki
  • Patent number: 5126148
    Abstract: Human hematopoietic cells produce metastasis-inhibitory factor (MIF). MIF exhibits a remarkable metastasis-inhibitory activity on viral diseases and immunopathies, as well as on malignant tumors. The MIF-producing human hematopoietic cells are easily proliferative by in vitro tissue culture and in vivo proliferation using a non-human warm-blooded animal. T cells exhibit a high MIF producibility. Mitogens augment the production of MIF when used as an MIF inducer.
    Type: Grant
    Filed: May 22, 1990
    Date of Patent: June 30, 1992
    Assignee: Kaisha Hayashibara Seibutsu Kagaku Kenkyujo
    Inventors: Masashi Kurimoto, Ryuichi Motoda, Kanso Iwaki